Two-part, Double-blind, Placebo-controlled, Randomized, Parallel-group Study: (Part 1) in Healthy Male Volunteers to Assess Safety and Tolerability of Ascending Repeated Oral Doses of BAY1817080, Followed by (Part 2), Two-way Crossover Administration of Four Different Doses in Patients With Refractory Chronic Cough to Assess Safety, Tolerability and Efficacy for Proof of Concept
Phase of Trial: Phase I/II
Latest Information Update: 14 Dec 2018
At a glance
- Drugs BAY 1817080 (Primary)
- Indications Cough
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Bayer
- 06 Dec 2018 Planned End Date changed from 17 Jul 2019 to 3 Jul 2019.
- 06 Dec 2018 Planned primary completion date changed from 5 Jun 2019 to 28 Feb 2019.
- 08 Nov 2018 Planned End Date changed from 28 Mar 2019 to 17 Jul 2019.